News

Praxis Precision Medicines (NASDAQ:PRAX) is a clinical-stage biopharmaceutical company specializing in therapies for central nervous system (CNS) disorders. On August 4, 2025, it reported financial

CMS Energy (NYSE:CMS), a major Midwest utility company providing electricity and natural gas to Michigan, announced its second-quarter 2025 results on July 31, 2025. The company reported

Although mighty American pharmaceutical company Eli Lilly (NYSE: LLY) has a dizzying number of commercialized products, it's a recently approved medication that's attracted outsized attention

Amicus Therapeutics (NASDAQ:FOLD), a specialist in rare disease medicines, delivered quarterly results on July 31, 2025 that notably surpassed expectations on both GAAP revenue and non-GAAP

Agios Pharmaceuticals (NASDAQ:AGIO), a biotechnology company focused on therapies for rare blood disorders, released its second quarter 2025 earnings on July 31, 2025. The headline was a notable

Glaukos (NYSE:GKOS), a medical technology company focused on novel ophthalmic therapies, announced its financial results for the second quarter on July 30, 2025. The company reported GAAP revenue of

Neurocrine Biosciences (NASDAQ:NBIX), a neuroscience-focused biopharma company, delivered a standout earnings report for the second quarter of fiscal 2025, released on July 30, 2025. The report

Integra LifeSciences (NASDAQ:IART), a medical technology company specializing in neurosurgery, reconstructive, and tissue technologies, released its results for Q2 2025 on July 31, 2025. The most

Amedisys (NASDAQ:AMED), a leading provider of home health, hospice, and high acuity post-acute care services, reported quarterly earnings for the period ending June 30, 2025, on July 29, 2025. The

Penumbra (NYSE:PEN), a medical device innovator focused on clot removal and vascular care, reported its second quarter 2025 results on July 29, 2025. The company delivered $339.5 million in GAAP

Chemed (NYSE: CHE) -- home to hospice care provider Vitas Healthcare and Roto-Rooter -- saw its shares decline 9% as of 1 p.m. ET on Wednesday, according to data provided by S&P Global Market

Alkermes Plc (NASDAQ:ALKS), a neuroscience-focused biopharmaceutical company, released its second quarter 2025 results on July 29, 2025. The standout news was a significant outperformance versus

Exelixis (NASDAQ:EXEL), an oncology-focused biotech, reported results for Q2 2025 on July 28, 2025. For the period, the company delivered non-GAAP earnings per share (EPS) of $0.75 in Q2 FY2025

Pacific Premier Bancorp (NASDAQ:PPBI), a commercial bank focused on business and specialty lending across the western United States, released its Q2 2025 financial results on July 24, 2025. The

Here's our initial take on Novocure's (NASDAQ: NVCR) fiscal 2025 second-quarter financial report.

Novocure reported no surprises in its latest quarter, with revenue up 6% for the year and both

A decade ago, shares of Exelixis (NASDAQ: EXEL), a biotech company specializing in oncology, were trading for under $10 per share. Today, the drugmaker's shares are changing hands for about $45